The biotechnology industry in Britain should be regulated and its clinical
trials scrutinised by independent scientists, says the House of Commons science
and technology committee in a report this week.
The report follows an inquiry into British Biotech, Europe鈥檚 largest biotech
company. Earlier this year its share price dropped by more than two-thirds after
allegations by its former head of clinical trials, Andrew Millar, that poor
results were being suppressed (This Week, 4 July, p 20).
鈥淲hat he did and said was in the public interest,鈥� says Alan Williams, deputy
chair of the committee.
Advertisement